Last year, 3,316 semaglutide overdoses were reported by 55 poison control centers in the U.S. Compounded versions, which can contain semaglutide salts, are likely behind most of the overdoses.
The makers of Ozempic are suing companies selling a compounded version of the diabetes, weight-loss medicine semaglutide and telling them to stop sales.
MCRA Expands its Cardiovascular Division, Hiring Fernando Aguel, Former Assistant Division Director, FDA Circulatory Support Devices
News provided by
Share this article
Share this article
WASHINGTON, May 20, 2021 /PRNewswire/ MCRA, LLC, a leading medical device and biologics advisory firm and clinical research organization (CRO) integrating US and International Regulatory, Clinical Research, Reimbursement, Healthcare Compliance, and Quality Assurance, is pleased to announce the hiring of Fernando Aguel as Vice President, Heart Failure & Circulatory Support Regulatory Affairs. Fernando previously served as U.S. Food and Drug Administration (FDA) Assistant Division Director, Circulatory Support Devices Team. MCRA s Cardio division continues to expand its expertise across all product areas in the cardiovascular space to provide clients with expert regulatory guidance, clinical study design and clinical trial execution.